Drugs / Yangxin Shengmai
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04270071 | Dec 2020 → Oct 2021 | coronary artery disorder | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yangxin Shengmai | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270071 ↗ |
| Known as | Yangxin Shengmai granules | “Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris” NCT04270071 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese patent medicine” NCT04270071 ↗ |
| Route | Oral | “given Yangxin Shengmai granules orally” NCT04270071 ↗ |